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Abstract 
Automatic quantification of cardinal histological features of non-alcoholic fatty liver disease 
(NAFLD) may reduce human variability and allow continuous rather than semi-quantitative 
assessment of injury. We recently developed an automated classifier that can detect and 
quantify macro-steatosis with ≥ 95% precision and recall (sensitivity). Here we report our early 
results on the classifier’s performance in detecting lobular inflammation and hepatocellular 
ballooning. Automatic quantification of lobular inflammation and ballooning was performed on 
digital images of H&E stained slides of liver biopsy samples from 59 individuals with normal liver 
histology and varying severity of NAFLD. Two expert hepatopathologists scored liver biopsies 
according the Nonalcoholic Steatohepatitis Clinical Research Network scoring system and 
provided annotations of lobular inflammation and hepatocyte ballooning on the digital images. 
The classifier had precision and recall of 70% and 49% for lobular inflammation, and 91% and 
54% for hepatocyte, ballooning. In addition, the classifier had an AUROC of 95% for lobular 
inflammation and 98% for hepatocyte ballooning. The Spearman rank correlation coefficient for 
comparison with pathologist grades was 45.2% for lobular inflammation and 46% for hepatocyte 
ballooning. Our novel observations demonstrate that automatic quantification of cardinal NAFLD 
histological lesions is feasible and offer promise for further development of automatic 
quantification as a potential aid to pathologists evaluating NAFLD biopsies in clinical practice 
and clinical trials. 
  
1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the U.S. affecting 
1 in 3 adults, and 1 in 8 children (1, 2). The most severe phenotype of the disease, non-
alcoholic steatohepatitis (NASH), is estimated to affect 3-5% of the U.S. population (3, 4). The 
spectrum of NAFLD begins with a mild phenotype, simple steatosis where only steatosis is 
present in the liver, and extends to NASH where steatosis is present with hepatic necro-
inflammation and fibrosis (5). Liver biopsy is the current “gold standard” diagnostic test for 
phenotyping NAFLD (5). Accurate phenotyping of NAFLD is critical because simple steatosis 
rarely progresses, whereas NASH can progress to cirrhosis, liver failure, and hepatocellular 
carcinoma (6-9). 
 
The NAFLD Activity Score (NAS), the state-of-the-art scoring system for liver biopsies, is based 
on the sum of three numerical grades determined by manual pathologist assessment and semi-
quantification of steatosis, lobular inflammation, and hepatocyte ballooning (10). These three 
lesions were selected for inclusion in the NAS based on a multiple logistic regression analysis 
that showed these lesions were independently associated with diagnosis of NASH (10). 
Because these lesions are potentially reversible in the short term, unlike fibrosis, they were 
chosen as end-points for therapeutic trials for NASH. A recent expert panel report 
recommended use of liver biopsy to define histological outcomes in phase 2 and 3 clinical trials 
in NASH and also recommended the use of NAS to define and quantify NAFLD activity (11).  
 
Semi-quantitative assessment of steatosis, lobular inflammation and hepatocyte ballooning has 
a couple important limitations stemming from the very nature of semi-quantitative grading that 
forces continuous measures to be threshold into discrete grading bins. The first limitation is 
semi-quantitative grades may fail to accurately show improvements. For example, a steatosis 
grade 0 implies 0-4% steatosis, whereas grade 1 implies 5-33% steatosis. Consider patient-A 
which enters a study with 7% steatosis, and improves by 3%. With this, patient-A improves from 
steatosis grade 1 to 0. Now consider patient-B who enters a study with 30% steatosis and 
improves 24%. Patient-B is a steatosis grade 1 before and at the end of the study. Looking at 
study results one may be led to believe patient-A’s 3% improvement was more significant than 
patient-B’s 24% improvement. The second limitation is semi-quantitative grading scale 
inevitably leads to inter and intra-rater variability (10, 12-17). Rater variability will be amplified 
for cases that lie near a grading cutoff (threshold), and may worsen based on the skills and/or 
training of the rater. 
 
We hypothesize that automated decision support tools for pathologists, by offering a continuous 
rather than semi-quantitative method for grading the histological lesions of NAFLD, could 
increase the precision and accuracy of grading histological activity. The aim of this initial study 
is to determine if an automated tool utilizing supervised machine learning could be trained by 
pathologists to detect lobular inflammation and hepatocyte ballooning.  Our group has 
previously published research demonstrating the feasibility of the accurate categorization of the 
white regions in liver biopsy images including macro-steatosis, central veins, portal veins, portal 
arteries, sinusoids and bile ducts (18). To date, no previous work has set out to automatically 
quantify lobular inflammation and hepatocyte ballooning.  
 
2. Materials and Methods 
The analysis discussed herein, is based on a dataset of 59 unique liver biopsy scans. Of the 59 
patients in the study, pathologist semi-quantitative grading was available for 47 patients with the 
remaining image scans being used solely for annotations and machine learning. Two study 
pathologists (DK, RK) provided semi-quantitative grades for each of the key histological lesions 
comprising the NAS (steatosis, lobular inflammation and hepatocyte ballooning). The patients in 
the study represented the full range of phenotypes from patients not having NAFLD, to those 
with various stages of NAFLD. 
 
High resolution digital images of the hematoxylin and eosin (H&E)–stained slides of liver biopsy 
images in the study were generated using the NanoZoomer scanner manufactured by 
Hamamatsu and housed in the Medical College of Wisconsin (MCW) pathology department. 
The images were scanned at 20X magnification and saved as RGB images in the lossless tiff 
file format. To create files small enough to efficiently work with given available hardware and 
computing resources, the files were reduced to 50% their original size. The smaller files are 
saved as RGB jpeg images with an 80% compression factor. The size reduction was performed 
with bicubic interpolation and antialiasing to preserve as much of the original image detail as 
possible. This resulted in a resolution of 0.92 microns per pixel with respect to actual tissue size. 
The research protocol was reviewed and approved by the Internal Review Board of the Medical 
College of Wisconsin. 
 
2.1 Quantification of lobular inflammation and hepatocyte ballooning in biopsy sections: 
Biopsy images are tiled into individual 25 pixel square sections. Tile size was selected by trial 
and error and by visual inspection of tile size appropriate with respect to lesion size. While there 
may be a more optimal tile size, our intent here is to show feasibility rather than develop a 
model intended for any specific use. Once an image is tiled, each tile is then assigned a 
probability of containing lobular inflammation and then automatically classified using a 
probability threshold as either containing lobular inflammation or not. The area of tiles classified 
as lobular inflammation versus the total area of the biopsy section is then computed to 
approximate the overall percentage of lobular inflammation. An identical process is also 
performed for quantifying the incidence of hepatocyte ballooning. Figure 1 pictorially 
demonstrates the process of classifying tiles for hepatocyte ballooning. 
 Our study pathologists used a custom built web-based Java Applet to manually annotate 138 
areas of lobular inflammation and 48 areas of hepatocyte ballooning on biopsy images. In 
addition, study pathologists annotated 291 regions of fibrosis, 128 regions of portal 
inflammation, and 1969 types of white regions inclusive of macro-steatosis, central veins, portal 
veins, portal arteries, sinusoids and bile ducts. Lobular inflammation and hepatocyte ballooning 
annotations are available as bounded polygons. These regions serve as the positive class for 
learning data in each of their respective learning tasks. It was also necessary to establish a 
negative class for learning. To accomplish this, two different types of negative regions were 
developed: 
 
1. Regions, excluding the positive class of interest (i.e. lobular inflammation or hepatocyte 
ballooning depending on the task). This includes macro-steatosis, central veins, portal 
veins, portal arteries, sinusoids and bile ducts, portal inflammation, fibrosis and a generic 
“other” class. 
2. Ten randomly selected tiles from each image. While there is no guarantee a randomly 
selected tile does not contain lobular inflammation (or hepatocyte ballooning), even in 
cases with high incidence of these lesions, there is a high probability a randomly 
selected tile does not contain the lesion.  
 
Because lobular inflammation and hepatocyte ballooning were annotated as bounded polygons, 
it was necessary to convert the polygon to a tile similar to what is used to quantify total 
incidence of lobular inflammation or hepatocyte ballooning. Figure 2 shows the feature process 
with shaded areas representing the tile image features are extracted for. The first is a tile 
centered on the polygon’s centroid (Figure 2b). The second is a tile randomly offset from the 
polygon centroid (2c). The motivation behind splitting polygon annotations into two different 
unique tiles is to first capture what a tile looks like should it fall directly on the lesion, and second 
to capture what it looks like if only part of the feature falls within a tile.  
 
For each positively and negatively labeled region, the types of features used by the classifier for 
learning are: 
• Texture - Texture and histogram statistics are computed for the gray scale region at 
each sigma level (19). 
• Gray level Co-Occurrence Matrix (GLCM) - The co-occurrence matrix is computed for 
pixels in the each region (20). 
• GLCM Statistics – Statistical measures related to the GLCM, such as contrast and correlation. 
• N-jet - For each sigma level in our scale representation we compute the 2-jet of the region 
and extract related statistics (21). 
• Nuclear Density - For each region, the mean, min, max and standard deviation of nuclear 
density are used as features (see discussion below). 
Accuracy of the classifier is measured in 2 ways. First, a data set consisting of positive and 
negative learning tiles is analyzed using a ten-fold cross validation to gauge overall accuracy of 
the classifier (22). Cross fold validation entails taking our dataset of positive and negative tiles 
and splitting the dataset into ten subsets, and then running experiments where a model is 
learned from data in nine of the subsets and tested against data in the tenth. To reduce 
variability the experiment is repeated ten times with each subset serving as the “tenth” test 
subset exactly once. Results are then aggregated across all ten experiments. Second, entire 
images are tiled into individual sections and the total area of tiles classified as lobular 
inflammation or hepatocyte ballooning versus the total area of the biopsy section is computed 
and correlated with pathologists’ semi-quantitative grades. 
 
2.2 Nuclear Density 
Lobular inflammation is most visible by the presence of the nuclei of inflammatory cells. As 
inflammatory cells are smaller than other nearby cells, the number of nuclei in inflamed areas is 
higher. To quantify this, a measure was established called Nuclear Density. The nuclear density 
metric for a given pixel P is measured as the number of pixels within a fixed radius of P that are 
also part of a nucleus. We hypothesized this metric would serve as a good proxy for quantifying 
inflammation as a higher concentration of inflammatory cells should yield a higher number of 
nuclei in a region, and consequently a higher nuclear density. 
 
The first step towards calculating nuclear density was to develop a process for isolating cell 
nuclei. Based on the hemotoxyphilic staining characteristics of nuclei, steps are taken to 
threshold nuclei from the biopsy images (23). Once the nuclei are extracted, it is possible to 
compute nuclear density. Nuclear Density for a pixel (x,y) and a surrounding radius r is defined 
as: 
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where R represents the set of pixels within radius r of (x, y) and f (i, j) = 1 if a pixel is identified 
as nuclei, and 0 otherwise. 
 
Using this equation for nuclear density, it is possible to calculate the nuclear density metric for 
all pixels in an image. Figure 3 shows a pictorial representation of the nuclear density 
calculations for an image. The nuclear density image clearly shows a high concentration of 
nuclei in this case caused by portal inflammation, stromal cells and other portal structures. 
While nuclear density statistics for an entire tissue section correlate with pathologist lobular 
inflammation grades, better concordance is obtained using the nuclear density measure as a 
feature for supervised learning experiments. 
 2.3 Precision and Recall 
The model’s performance for detecting lobular inflammation and hepatocyte ballooning is 
measured by calculating the precision and recall (specificity) rates. Precision (also known as 
“Positive Prediction Rate”) is a measure of the model’s positive predictive ability. Specifically, 
we are measuring what percent of tiles classified as containing a given lesion type are correct. 
For both lobular inflammation and hepatocyte ballooning, precision is measured as: 
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Recall is the fraction of all positive tiles that are detected for each lesion type. For lobular 
inflammation, recall is the percent of all tiles that actually contain lobular inflammation that are 
correctly identified. Mathematically, recall is measured as: 
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3. RESULTS 
3.1 Histological characteristics of subjects 
Pathologist scored H&E liver biopsy slides from 47 (20 with normal liver histology and 27 with 
NAFLD of varying severity) of the 59 total patients in our dataset according to the NAS scoring 
system (10). The remaining 12 image scans were used only for annotations and machine 
learning. In the NAFLD group, 19 subjects had simple steatosis and 8 had NASH. Figure 4 
shows the pathologist grading distribution of lobular inflammation and hepatocyte ballooning 
amongst the 47 patients. Across our data set, a total 138 areas of lobular inflammation and 48 
areas of hepatocyte ballooning were annotated on biopsy images.  
 
As shown in Figure 4, our data set is skewed towards cases with minimal findings of lobular 
inflammation and hepatocyte ballooning. This does not present an immediate problem for our 
analysis as our focus is on the precision and recall (sensitivity) of our model to correctly classify 
individual image tiles. Additional data would, however, be needed across the full spectrum of 
lobular inflammation and hepatocyte ballooning grades to draw more meaningful conclusions 
about the impact of false positives and false negatives on quantifying an entire tissue sample. 
 
3.2 Automatic Quantification of Lobular Inflammation 
Evaluation of lobular inflammation classification is carried out using a 10-fold cross validation 
experiment  
 
It is important to point out that our dataset of tiles is heavily skewed towards negative examples 
(tiles without lobular inflammation). Experiments were intentionally designed with a large skew 
towards tiles without lobular inflammation as even in patients with high incidence of lobular 
inflammation, the number of tiles without lobular inflammation would significantly outnumber 
those with lobular inflammation. The model classifies lobular inflammation with a 0.70 precision 
and 0.49 recall (sensitivity).  
 
In the cross validation experiment, 95.6% of tiles were classified correctly. This represents a 
statistically significant improvement over the baseline accuracy of 94.0% (p-value <0.001) 
obtainable by always predicting not lobular inflammation. While the accuracy metric is not a 
clinically meaningful, it demonstrates the improvements over naïve baseline methods based on 
the predictive power of the model. 
 The recall-precision curve is shown in Figure 5 along with the ROC curve for the experiment. 
Examination of both of these curves to evaluate classifier performance is important as our data 
set is largely skewed towards negative non-lobular inflammation examples (24). Namely, with a 
ROC curve the goal is to be towards the “upper left” of the curve, while with precision-recall 
curves the goal is to be near the “upper right”. The ROC curve has a large area under the curve 
(AUROC) of 0.946 indicating the model has a strong ability to discriminate between tiles with 
lobular inflammation and those without.  
 
While the immediate focus of our research was the accurate identification of individual tiles of 
lobular inflammation, we also sought to gauge model performance by measuring how it 
compared to pathologist grades. For each patient, the overall percentage of tissue with lobular 
inflammation was calculated by taking the total area of tiles classified as having lobular 
inflammation and dividing by total tissue area. The motivation for this metric in our analysis is 
tiles containing lobular inflammation would approximately represent 1 focus of lobular 
inflammation, and the metric would therefore be proportional to the number of lobular 
inflammation foci per unit area of tissue. To obtain percentage lobular inflammation, a different 
model was created for each patient using only training data from other patients, otherwise 
known as a leave-one-sample out approach.  
 
There is a general concordance between the modeled percent lobular inflammation and 
pathologist grade. The four patients that received the highest pathologist grades all rank near 
the top of the model. Conversely, those with the lowest grade score near the bottom (Figure.6). 
Case FLE038 stands out as an outlier in the analysis. Examination of the case revealed this 
tissue sample is considerably smaller by surface area compared to the other samples in our 
study. In fact the FLE038 sample was ~ 75% smaller than the mean size of all samples. As 
evident in this case, a smaller tissue section would be far more susceptible to the impact of false 
positive tiles. The overall spearman rank correlation for the comparison between the model and 
average of the pathologists score is 0.452 with a p-value of 0.002.  
 
3.3 Automatic Quantification of Hepatocyte Ballooning 
Similar to lobular inflammation, evaluation of the hepatocyte ballooning classifier was carried out 
using a 10-fold cross validation experiment. The model classified hepatocyte ballooning with 
0.91 precision and 0.54 recall. As with lobular inflammation, the dataset is skewed heavily 
towards examples without hepatocyte ballooning. Based on this a baseline accuracy of 97.9% 
would be obtainable simply by always predicting not hepatocyte ballooning for every tile. In our 
model, 98.9% of regions were correctly classified. This is a statistically significant (p-value 
<0.001) improvement over the baseline method. As with lobular inflammation the high level of 
accuracy has no clinical meaning, but it does demonstrate the predictive ability of the model and 
show a gain over a naïve baseline method.  
 
With the dataset skewed heavily towards examples without hepatocyte ballooning, classifier 
performance must be evaluated through examination of both the recall-precision curve and the 
ROC curve (Figure.7). The ROC curve shows the model has a strong ability (AUROC of 0.983) 
to discriminate between tiles as having or not having a ballooned hepatocytes. Similarly, the 
precision-recall curve shows a very high precision rate of 90% is obtainable while still recalling 
more than 50% of all tiles containing ballooned cells. This confirms that the model performs well 
despite the skew towards negative instances. 
 
The next step in the analysis was to examine the concordance of a continuous metric derived 
from model predictions of hepatocyte ballooning with scores provided by our expert 
pathologists. For each patient, we took the surface area of tiles classified as containing 
hepatocyte ballooning and divided by total tissue area. This metric should be approximately 
equal to the percentage of tissue area containing hepatocyte ballooning if all tiles are correctly 
classified. The model obtained a spearman rank correlation of 0.460 and a p-value = 0.001 with 
our pathologist grades. 
 
Figure 8 shows the results of each individual case. The chart shows a good relationship 
between average pathologist grade and the computed percentage of ballooning with cases that 
received a higher pathologist grade typically receiving a higher computed percentage 
ballooning. This is particularly prevalent on the two cases that received the highest grades from 
study pathologists. FLE008 received a score of 2 from both RK and DK, and FLE029 received a 
score of 0 and 2 from RK and DK, respectively. These two patients received the 2nd and 3rd 
highest overall percentage ballooning from the model. Case FLE021 presents as an obvious 
outlier. Examination of the case more closely revealed the model was misclassifying 
glycogenosis as hepatocyte ballooning. There are several cases that received a grade 0 from 
both study pathologists but where the model detected some hepatocyte ballooning. These 
cases are all the result of 1-3 tiles in the entire image being false positives. As the model had a 
far higher precision (positive predictive rate) than recall (sensitivity) of tiles, the impact of just a 
few false positives is seen in these cases. 
 
4. DISCUSSION 
The results of this study demonstrate that it is feasible to develop a system using supervised 
machine learning to automatically quantify two of the cardinal features needed to phenotype 
NAFLD, lobular inflammation and hepatocyte ballooning. These findings are significant as more 
accurate continuous measurements are more desirable than semi-quantitative scores to 
measure NAFLD activity and quantify patient’s response to therapeutics used in trials or patient 
care. 
 While the overall test statistics for correlation with pathologist grade are not as high as those our 
research group has shown for steatosis grading (12, 18), they show a general concordance 
between the model scores and pathologist grades and demonstrate the feasibility of such an 
approach. While our ultimate goals are to replace discrete grades with continuous measures of 
lesions, we thought it important to show the general relationship between continuous measures 
and pathologist grade. It is important to note that the continuous metrics we used in our analysis 
are different than the metrics used by pathologists for semi-quantitative grading. Both our 
continuous metric and pathologist grade should, however increase with lesion prevalence. 
Correlation coefficients may also be of limited meaning as we are correlating 47 continuous 
values to four discrete bins of average pathologist grade. Further, our data set is skewed 
towards patients with minimal incidence of lobular inflammation and hepatocyte ballooning so 
additional research is needed to examine model performance on more severe cases.  
 
Due to the large skew in the dataset of tiles without lobular inflammation or hepatocyte 
ballooning, a large increase in the number of false positives (i.e. incorrect predictions of lobular 
inflammation or hepatocyte ballooning) would have a minimal impact on the false positive rate. 
This is because the metric is calculated as (false positives) / (false positives + true negatives), 
and the true negatives (correct predictions of not lobular inflammation or hepatocyte ballooning) 
in the denominator will dominate the metric. Based on this, one must also look to the recall-
precision curve to evaluate the classifier. Specifically, the precision rate is not susceptible to the 
large skew of negative examples in the data set. Examination of the recall-precision curve 
shows predictions of lobular inflammation may be made with approximately 65% precision, 
while still recalling 50%+ of all lobular inflammation. A decrease in recall rate should be an 
acceptable tradeoff for increased precision in this experiment, provided recall is consistent 
across patients from different labs, cutting and staining procedures, etc. In other words, if 
patient A has more lobular inflammation than patient B, identifying 50% of patients A’s lobular 
inflammation will still quantify to a higher score than recalling 50% of patient B’s. 
 
Examination of the classifier results showed areas with glycogen and/or many fat droplets 
confusing the detection of hepatocyte ballooning. Example 2 of Figure 1 shows such a case. In 
Example 2, a ballooned cell adjacent to small fat droplets(upper-left of Figure 1, Example 2) is 
correctly identified. However, another ballooned cell located in between the three steatotic cells 
with large fat droplets at the bottom right of the example is missed. The model assigned this tile 
23% chance of containing hepatocyte ballooning demonstrating that the model detected some 
ballooning activity, however, this fails to meet the threshold for being considered a positive 
detection of hepatocyte ballooning. Examination of the tile probabilities of Example 2 also shows 
an overall increase in the probability of ballooning activity in tiles where no ballooning exists 
presumably do to the appearance of the cytoplasm. Future models should include more training 
examples of both the positive and negative ballooning class in areas of glycogen or high 
steatotic cells incidence to afford the classifier a richer training set to make correct predictions in 
these areas. In practice, a tool could be developed that pre-sorts tiles by probability allowing an 
interactive step whereby a pathologist makes the final determination. 
 
The continuous measures used herein are based on surface area of tiles with lesions divided by 
the total surface area of tissue. This metric can likely be improved by modifying the 
denominator. Specifically, rather than total surface area of tissue, it may be desirable to use 
total surface area of tissue excluding portal regions. This may more accurately reflect disease 
activity in the regions of primary interest for a given lesion. 
 
No previous efforts have been published attempting to automatically quantify lobular 
inflammation and hepatocyte ballooning in images of scanned NAFLD liver biopsy sections. 
Automatic quantification of lobular inflammation and hepatocyte ballooning may provide a 
means for reducing the inherent human variability in semi-quantitative assessment of NAFLD 
histology and provide pathologists a reliable tool for measuring NAFLD lesions on a continuum. 
Furthermore, continuous accurate measurement of NAFLD cardinal histological features, such 
as steatosis, lobular inflammation, hepatocyte ballooning and portal inflammation, is highly 
desirable in assessing NAFLD disease activity and monitoring response to therapeutic 
interventions in clinical trials.     
 
In summary, this is the first study showing that automatic quantification of lobular inflammation 
and hepatocyte ballooning is feasible in digital images of liver biopsies from patients with 
NAFLD. We are currently conducting studies to optimize and validate the performance of our 
automated classifier and are also developing algorithms for automated quantification of hepatic 
fibrosis. These studies will include exhaustive annotation of unseen test cases so the 
performance of our model may be reported on the ability to identify all lesions on a given tissue 
sample, rather than proxy metrics based on a subset of annotated tiles. These early findings 
offer promise for further development of automatic quantification as a potential aid to 
pathologists evaluating NAFLD biopsies in clinical practice and clinical trials. 
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Figure 1. The process of identifying hepatocyte ballooning.  Actual results and tiles are shown for 
two different biopsy sections. Original scanned images are first divided into tiles. Each tile is 
assigned a probability of containing hepatocyte ballooning (black is a probability of 0, middle gray 
is 50%, and white is 100%). Last a threshold is determined for what probability is required for a tile 
to be automatically classified as hepatocyte ballooning.  
 
Figure 2. Features extracted for machine learning experiments to simulate the effects of image 
tiling for classification. (a) A polygon annotation. (b) Features are extracted for a tile centered on 
the polygon’s centroid. (c) Features are extracted for a tile randomly offset from the polygon’s 
centroid. 
 
Figure 3. Creation of a heat map representing the nuclear density. 
 
Figure 4. Distribution of pathologist grades for lobular inflammation and hepatocyte ballooning. 
 
Figure 5. Precision vs. Recall and ROC curve for lobular inflammation. 
 
Figure 6. Comparison of average pathologist grade to model percentage for lobular inflammation. 
 
Figure 7. Precision vs. Recall and ROC curve for hepatocyte ballooning. 
 
Figure 8. Comparison of average pathologist grade to model percentage for hepatocyte 
ballooning. Patient in FLE021 suffers from glycogenosis, a condition similar in appearance to 
hepatocyte ballooning. 
 
Highlights 
 We examine automated detection of lobular inflammation and hepatocyte ballooning on 
digital imaged of liver biopsy 
 The models had precision and recall (sensitivity) of 70% and 49% for lobular 
inflammation 
 The model had precision and recall (sensitivity) and 91% and 54% for hepatocyte, 
ballooning. 
 We demonstrate that automatic quantification of cardinal NAFLD histological lesions is 
feasible. 
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